PaulaRaffinPohlmannMD

Oncology • Houston, TX

Breast Cancer, Hematologic Oncology

Associate Professor and Chief of Clinical Research, Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center

Join to view full profile

Dr. Pohlmann is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pohlmann's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Fax+1 713-794-4385

Education & Training

Vanderbilt University Medical CenterResidency, Internal Medicine, 2009 - 2011
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Federal University of Rio Grande do Sul School of MedicineClass of 1992

Certifications & Licensure

AZ State Medical License 2023 - 2027
GA State Medical License 2023 - 2026
TN State Medical License 2023 - 2026
AL State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2023 - 2025
TX State Medical License 2021 - 2025
WA State Medical License 2023 - 2025
DC State Medical License 2013 - 2022
MD State Medical License 2014 - 2017
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013

Clinical Trials

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases Start of enrollment: 2012 Feb 01
Active, not recruiting
Phase 2
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) Start of enrollment: 2013 May 01
Active, not recruiting
Phase 2
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery Start of enrollment: 2013 Dec 13
Active, not recruiting
Phase 3
Phase 1 Safety Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies Start of enrollment: 2014 Mar 01
Unknown status
Phase 1
Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients Start of enrollment: 2017 Jan 31
Completed
Phase 2
Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer Start of enrollment: 2017 Aug 29
Active, not recruiting
Phase 2
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer Start of enrollment: 2018 Jun 21
Active, not recruiting
Phase 2
Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery Start of enrollment: 2018 Oct 08
Terminated
Phase 2
WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor Start of enrollment: 2019 Apr 01
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial.
Kim A Reiss, Mathew G Angelos, E Claire Dees, Yuan Yuan, Naoto T Ueno
Nature Medicine. 2025-02-07
Human Epidermal Growth Factor Receptor 2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.
Mohamed A Gouda, Amrit Gonugunta, Ecaterina E Dumbrava, Timothy A Yap, Jordi Rodon
Clinical Cancer Research. 2025-01-22
1 citations
A First-in-Human Study of Cinrebafusp Alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies.
Sarina Piha-Paul, Shane A Olwill, Erika Hamilton, Anthony Tolcher, Paula Pohlmann
Clinical Cancer Research. 2025-01-17

Press Mentions

A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with Durable Responses in Patients with HER2-Mutated MBCJanuary 29th, 2025
MD Anderson Research Highlights for January 22, 2025January 22nd, 2025
MD Anderson Unveils January 2025 Research Breakthroughs in Cancer ScienceJanuary 22nd, 2025
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Association for Cancer Research - AACR
Member
American Medical Association - AMA
Member

Other Languages

Portuguese